Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
In this Review, we trace the recent evolution of obesity pharmacotherapy from GLP1 receptor agonists to next-generation multi-receptor agonists, alongside strategies that incorporate oral formulations, weight-loss quality approaches and tissue-specific drug targeting
Thompson PM, Giedd JN, Woods RP, MacDonald D, Evans AC, Toga AW
Each cycle from cold to warm and back again stresses the peptide structure
Preiss, J
Side effects, if they occur, are typically mild and temporary
Methods This systematic review and meta-analysis, registered in PROSPERO and conducted per PRISMA guidelines, assessed the effects of GLP-1RA use on AUD and alcohol-related outcomes in adults with obesity or type 2 diabetes mellitus
US$ 21.27
US$ 23.86
US$ 29.45
US$ 28.01
US$ 28.07
